FindTrial
Sign In

Estimation of the activity of marker enzymes ( Paraoxonase 1,Myeloperoxidase) in serum and their relationship with Atherogenic Index of Plasma in patients with abnormal lipid levels

Serum Paraoxonase 1, Myeloperoxidase activity and their association with Atherogenic Index of Plasma in patients with Dyslipidemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/01/017177
Enrollment
390
Registered
2019-01-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I709- Other and unspecified atherosclerosis

Interventions

None listed

Sponsors

Tejal Deepak Durgekar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy controls with normal lipid profile. 2.Patients having dyslipidemia with and without cardiovascular complications will be included.

Exclusion criteria

Exclusion criteria: 1. Patients with renal failure, chronic Kidney Disease, triglycerides levels greater than 500 mg/dl, diabetes with glycated Hemoglobin greater than 9 will be excluded.

Design outcomes

Primary

MeasureTime frame
Measuring serum Paraoxonase 1(PON1) , Myeloperoxidase(MPO) activity, Atherogenic Index of Plasma (AIP), Effect of Statin therapy on PON1, MPO and AIPTimepoint: six months—

Secondary

MeasureTime frame
Assessing risk prediction of cardiovascular disease.Timepoint: six months—

Countries

India

Contacts

Public ContactDr Shobha U Kamath

Kasturba Medical College Manipal

shobha.kamath@manipal.edu9845865848

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026